In the past few years, a defect in acid neuraminidase (sialidase) activity has been demonstrated in several disorders presenting various clinical phenotypes. Neuraminidase deficiency has also been demonstrated in another group of patients originally found to have a 0-galactosidase deficiency ( 14, 16) . In these cases the neuraminidase deficiency was inferred to be the primary metabolic block responsible for the P-galactosidase deficiency since Pgalactosidase levels in the parents of affected patients were generally not reduced. Complementation analysis between cell lines obtained from patients deficient in both P-galactosidase and neuraminidase (P-gal-lneur-) with those from patients affect'ed only by neuraminidase deficiency (ML I) have been reported by two laboratories but with differing conclusions (9, 10) . Using a heterokaryon enrichment procedure, Mueller and Shows (13) recently presented convincing evidence of restoration of neuraminidase activity after fusion of ML I fibroblasts with those from 0-gal-lneur-. Furthermore, Hoogeveen et ul. (8) showed that the combined deficiency of P-gal-lneur-in human fibroblasts in culture can be partially corrected by the addition of concentrated culture medium collected from several mutant lines of human fibroblasts, including those with isolated P-galactosidase (GMI gangliosidosis) or neuraminidase (ML I) deficiency. Similar corrective effects were observed by these authors by treating P-gal-lneur fibroblasts with the protease inhibitor leupeptin (5) . Suzuki et ul. (1 5 ) were able to confirm this corrective effect with leupeptin for P-galactosidase but not neuraminidase.
In order to help clarify the metabolic defect responsible for the combined P-gal-lneur deficiency we have conducted complementation, cross correction, and drug correction studies on fibroblasts obtained from a patient with the infantile form of combined P-gal-lneur-that we have followed for the past 8 yr (1). These studies provided additional support for the proposal recently made by d'Azzo et al. (3) that the combined P-gal-/ neur-deficiency is not due to a defect in the structural gene for 0-galactosidase or neuraminidase, but rather in a glycoprotein which is normally required to protect these two enzymes against intralysosomal degradation. CO. in minimum essential medium (MEM Earle's medium, Gibco), supplementd with 15% heat-inactivated fetal calf serum (Gibco), 1 m M sodium pyruvate, 100 U/ml penicillin, and 100 pglrnl streptomycin sulfate. Cells were harvested 1-2 wk after subculture. Fibroblasts harvested from 100-mm Petri dishes (Corning) were, after trypsinization, resuspended in either phosphate buffered saline or normal saline (0.9%) and washed twice in the same solution by resedimentation in a clinical centrifuge. The cell pellet was then resuspended in 0.5 ml of distilled water and homogenized in a Duall-type homogenizer with 10 strokes before enzymatic assays and protein determinations. Fibroblasts harvested from 35-mm Petri plates (Corning) were processed for protein and enzymatic assays as described above, except that the cells were washed with normal saline and then scraped from the plates without prior trypsinization. Fibroblasts used for "cross correction" studies were grown in 35-mm Petri dishes (Corning) at 37°C in minimum essential medium without bicarbonate, supplemented with 15 % heat-inactivated fetal calf serum (Gibco), I mM sodium pyruvate, 100 U/ml penicillin, 100 pg/ ml streptomycin sulfate, and 5% buffer consisting of 10 m M sodium phosphate, 15 m M BES, 10 mM PIPES: pH 6.8, and 0.5% bicarbonate.
MATERIALS AND METHODS

Muteriuls
Collection (~f',fihrohla.st secretions. Fibroblasts from the cell lines described above were grown to confluence in 490-cm' roller bottles (Corning). The growth medium was then replaced by 50 ml of serum-free Waymouth medium (KC Biological) containing 10 m M NH,CI. The NH4C1 greatly enhances the secretion of "high-uptake" forms of acid hydrolases (7) . The cells were maintained at 37°C for 24 h at which time the media was collected and replaced with 50 ml of fresh media. The collections were continued for 1 wk at which time the 7-24-h collections from each individual cell line were pooled, concentrated (-100-fold) and dialyzed against phosphate buffered saline on an Amicon PM 10 membrane filter.
Enzvmatic u.ssuys andprotein determination. Enzymatic activities were determined fluorometrically as previously described in part (6) . Synthetic sitbstrates used were 4-methylumbelliferyl-P-D-glucuronide, 10 m M in 0.1 M sodium acetate buffer, pH 4. of cell homogenate (10-100 pg protein) to 100 PI of substrate and incubated at 37°C for 30-60 min. except a-neuraminidase activity was measured by incubating 10 p1 of cell homogenate with 30 p1 of 0.1 M acetate buffer, pH 4.4 and 15 of fluorometric substrate. Reactions were stopped by the addition of 1.8 ml of glycine carbonate buffer, pH 10.5. All assays were performed in duplicate. One unit of enzyme activity is defined as the amount of enzyme that releases 1 nmol of 4-methylumbelliferone per h. a-Neuraminidase activity was also measured using ['Hllabeled sialyllactose as the substrate by the method described by Frisch and Neufeld (4) Completnentation studies. Fibroblasts for complementation analysis were seeded at a ratio of 1: 1 with each parental line and cultivated for 3 d in minimal essential medium (MEM Earle's medium, Gibco), supplemented with 15% heat-inactivated fetal calf serum (Gibco), 1 m M sodium pyruvate, 100 U/ml penicillin, and 100 pg/ml streptomycin sulfate. Hybridization was then carried out by the addition of 42% (w/v) polyethylene glycol 1000 as described by Hoogeveen et al. (9) .
Cross correction .studies. We studied the effects of "corrective factor" isolated from two sources on the activities of P-galactosidase and a-neuraminidase in P-gal-lneur fibroblasts and other mutant cell lines. In one case we added 100 p1 of concentrated secretions prepared from human fibroblasts (as described above) to 1.0 ml of medium which was then added to different mutant cell lines for 12 h to 3 d. @-Galactosidase and a-neuraminidase activities in these cells were measured at the times indicated in the figures. Correction was also studied by the addition of concanavalin A binding glycoproteins isolated from human spleen with modifications of a procedure described earlier (12) . Human spleen was minced with a razor blade and then homogenized with a Polytron in 5 volumes of buffer A (0.025 M sodium tartrate, 0.025 M EDTA, pH 6.3). Deoxycholate (I %) was then added to a final concentration of 0.2%, the preparation homogenized a second time with a Polytron, and placed on ice for 30 min. The crude homogenate was centrifuged for 20 min at 10.000
x g, the supernatant removed, the pellet re-extracted in a small volume of buffer A, and centrifuged again. The supernatant from the second extraction was combined with the first and solid ammonium sulfate was added to a final concentration of 55%. The preparation was stirred for 45 min at 4°C and the pellet collected by centrifugation for 30 min at 10,000 x g. The pellet was resuspended and dialyzed against buffer B (10 m M Tris, 10 mM NaH2P04, 100 m M NaCI, pH 7.5). The dialyzed sample was applied to a column of concanavalin A-Sepharose (5.0 ml of packed beads) equilibrated with buffer B at 4°C. The column was then washed with 10 column volumes of buffer B and eluted at room temperature with 7 column volumes of buffer B containng 0.75 M a-methylmannoside. The eluate was dialyzed against buffer B and concentrated on a n Amicon PM 10 filter to a final protein concentration of 1 1 mg/ml. An aliquot (50 PI) of this preparation was added to 1.0 ml of medium which was then incubated with different mutant cell lines for 12 h to 3 d.
RESULTS
C'ompl~mentatton stzldirs. T o study the genetics of our patient with the infantile form of combined n-galactosidase-neuraminidase deficiency (P-gal-lneur-) we have conducted complementation analysis by somatic cell hybridization to produce heterokaryons. Each of the parental cell types used in the complementation studies were deficient in a-neuraminidase, P-galactosidase, or both activities. Neuraminidase activity in fibroblasts obtained from the P-gal-lneur patient was partially restored by fusion with two M L 1 cell lines (Table I) . After fusion, neuraminidase activity in the heterokaryons was restored to 9-16% of mean levels for control fibroblasts. Complementation was also observed following fusion with an M L I1 cell line. Here activity of neuraminidase reached 22% of mean control levels after fusion (Table 1) . No increase in neuraminidase levels was observed following parental fusion.
We also tested the 8-gal-/new-fibroblasts for complementation with regard to 8-galactosidase by fusion with M L I1 fibroblasts and fibroblasts from a G,,, gangliosidosis cell line. As observed with neuraminidase activity, P-galactosidase showed complementation with an increase in activity when fused with the ML 11 cell line (17% of mean control levels) and the GM, gangliosidosis fibroblasts (26% of mean control levels) ( Table 2) . These results suggest that the gene mutation in our 8-gal-lneurpatient is different from the mutations observed in ML I, M L 11, or Gw I gangliosidosis.
The small increase in neuraminidase (Table 1) and P-galactosidase (Table 2 ) levels we observed during co-cultivation may indicate the uptake by the 0-gal-lneur-fibroblasts of a "corrective factor" secreted by the Gu, gangliosidosis or M L I fibroblasts.
Similarly. in co-cultivation studies reported by Hoogeveen et al. (9) , neuraminidase activity increased 5-7-fold in 8-gal-/newcells as a result of the transfer of a "corrective factor" secreted by ML I fibroblasts. The small increase in neuraminidase and 8-galactosidase activities we observed during co-cultivation of Pgal-/new-fibroblasts with ML 11 fibroblasts is unexpected because secretions from ML I1 fibroblasts fail to correct 0-gal-/ n e u r fibroblasts (9) .
Cross correction .stlldic.s. Both Gvi gangliosidosis and sialidosis fibroblasts produced a "corrective factor" which was pinocytosed by the p-gal-lneur fibroblasts leading to partial correction of its deficiencies for these two enzymes. Concentrated secretions produced by a GXII gangliosidosis cell line in the presence of NH,C1 wcre added to the medium above 8-gal-/new-fibroblasts. A time dependent correction of 8-galactosidase (23% of mean control levels) and neuraminidase activities (1 1 % of mean con- Fig. I . Partial correction of 0-galactos~dase activity in [j-gal-incurfibroblasts after addition of fibroblast secretion "corrective factor." Fibroblasts were grown to confluence in 35-mm Petri dishes. At time zcro. 100 pl of concentrated secretions collected from GMi gangliosidosis fibroblasts were added to each plate in 1.0 ml of medium in the absence ( 0 ) or presence ( 0 ) of 2 mM mannose-6-phosphate. At the times ilidicated 6-galactos~dasc activity was determined in duplicate plates. Fig. 2 . Partial correction of n-neuraminidase activity in p-gal-incurfibroblasts after addition of fibroblast secretion "corrective factor." Fibroblasts were grown to confluence in 35-mm Pctri dishes. At time ~c r o , 100 of concentrated secretions collected from GMI gangliosidosis fibroblasts were added to [j-gal-/neur fibroblasts in 1.0 ml of medium in the absence ( 0 ) or presence ( 0 ) of 2 mM mannose-6-phosphate or to ML I fibroblasts without added mannose 6-phosphate (M). At the tlrnes indicated (u-neuraminidase activity was determined In duplicate plates. trol levels) were observed for the 8-gal-lneur-cells but no correction of neuraminidase was observed in control M L I cells (Figs. 1 and 2 ). Identical results were observed when secretions collected from ML I fibroblasts were used as the source of "corrective factor." Here 8-gal-/new fibroblasts displayed partial correction of neuraminidase and 0-galactosidase activities whereas Gbll gangliosidosis controls showed n o increase in 0-galactosidase activity (data not shown). The secretions collected from the 8-gal-lneur fibroblasts had no corrective activity. The presence of mannose-6-phosphate (2 mM) in the medium during incubations with "corrective factor" inhibited the partial correction of p-galactosidase and neuraminidase activities in thc pgal-/neur cells (Figs. I and 2 ). This result suggests that the "corrective factor" is pinocytosed via the phosphomannosyl receptor present on fibroblasts, the receptor responsible for the uptake o f many acid hydrolases. Furthermore, this partial cor- (Fig. 3 ).
F T E R A D D I T I O N O F C O R R E C T I V E FACTOR
---~. neuraminidase activity to 1 1 % o f mean control levels (Fig. 4) . O-llexosaminidasc 9525 I0563 10022 This increase is not due to the uptake o f neuraminidase or P-n-galactosidase 6 7 67 galactosidase present in the spleen glycoprotein preparation be- 4: Leupeptin at a final concentration of 30 1 M was dissolved directly ' into growth medium.
$ EP475 at a final concentration of 20 FM was soluble in the growth medium when neutralized by the addition of an equimolar amount of 0 a NaHCO?.
? - At time zero this m e d~u n i was preplaced by 1.0 ml of fresh medium q 2 without "corrective factor" and at the times indicated 8-galactosidasc (B))
and tu-ncuraminidase (0) ativities were determined in dulicate plates. Table 3) . Unlike the effects
HOURS A F T E R A D D I T I O N O F
seen with "corrective factor" from either concentrated fibroblasts
secretions or glycoproteins isolated from human spleen these Fig. 4 . Partial correction of ,8-galactosidase and a-neuraminidase ac-protease inhibitors caused no significant improvement o f neurtivity in p-gal-Jneur fibroblasts after addition of "corrective factor" aminidase levels. Furthermore, they had no effect on the activiisolated from human spleen. Fibroblasts were grown to confluence in ties o f several other acid hydrolases ( Table 3) . Addition o f 35-mm Petri dishes. At time zero. 50 ~1 of glycoproteins isolated from leupeptin to ML I or GMI gangliosidosis fibroblasts had no effect human spleen were added to p-gal-lneur-fibroblasts. At the times on the activities o f neuraminidase, P-galactosidase, or the activindicated 8-galactosidase ( 0 ) and a-neuraminidase (B)) activities were ities o f the other acid hydrolases measured in Table 3 (data not determined in duplicate plates.
shown). The partial corrective effect o f leupeptin on P-galacto-sidase activity persisted for at least 2 d after removal of the drug, even in the presence of cycloheximide (Fig. 5) . This result suggests that the sustained increase in P-galactosidase activity after removal of leupeptin is not dependent on new protein synthesis. Apparently, P-galactosidase accumulated in the presence of leupeptin is stable after its removal.
DISCUSSION
The clinical features of this American case of infantile combined 0-galactosidase/neuraminidase deficiency have been summarized elsewhere (I), together with those of a similar Italian patient whose fibroblasts were studied by Galjaard et a/. (5) . Our findings that partial restoration of neuraminidase activity occurs after fusion of 0-gal-lneur fibroblasts with two ML I cell lines and an ML I1 cell line indicate that separate gene mutations are responsible for these diseases. Our results support those in a recently published report by Mueller and Shows (1 3), who used a heterokaryon enrichment procedure, and obtained an increase in neuraminidase activity that approached control values. Hoogeveen et a/. (9) using fusions similar to ours, also found moderate increases in neuraminidase activity; however, Kato et a[. (10) failed to demonstrate detectable increases in neuraminidase activity. The reasons for the discrepancy of Kato's findings with the other studies including this one are not clear. The restoration of P-galactosidase activity after fusion of G M I gangliosidosis or ML I1 cells with 0-gal-lneur-fibroblasts suggests that different gene mutations, leading to the impairment of p-galactosidase, are involved in these disorders.
The partial correction of P-galactosidase and neuraminidase activities observed in 8-gal-lneur-fibroblasts after the addition of concentrates of culture medium obtained from GMi gangliosidosis or ML I fibroblasts also supports our conclusions obtained from the complementation studies. Specifically, that the metabolic defect in the 8-gal-lneur-is different from the basic defect responsible for G M , gangliosidosis or sialidosis. Concentrated medium obtained from 8-gal-lneur-fibroblasts is unable to correct itself. Cross correction studies published recently by Hoogeveen et ul. (8) reached conclusions similar to ours.
The ability of mannose-6-phosphate to inhibit the partial correction of p-galactosidase and neuraminidase activities when media concentrates were added to /3-gal-lneur cells suggest that the "corrective factor" is being taken up by the fibroblasts via phosphomannosyl receptors present on the cell surface. These are the receptors responsible for the uptake of a variety of acid hydrolases by fibroblasts in culture. This suggests that the "corrective factor" could be an acid hydrolase itself or some other phosphoglycoprotein necessary for full enzymatic expression of 0-galactosidase and neuraminidase. This conclusion agrees with the observation that medium collected from I-cells, which are unable to phosphorylate their acid hydrolases, does not correct fl-gal-/neur-fibroblasts (9) . The fact that the partial correction of P-galactosidase and neuraminidase activities persists for at least 3 d after removal of the "corrective factor" supports the argument that it may be important in stabilizing these two enzymes.
Another rich source of "corrective factor" was found to be glycoproteins isolated by chromatography of human spleen homogenates on concanavalin A-Sepharose. Glycoprotein preparations made in a similar manner from human placenta or human liver were effective in partially correcting neuraminidase levels but were ineffective in the correction of p-galactosidase activity (8) . The apparent discrepancy between our results with spleen and those reported by others (8) with liver or placenta can be explained by the fact that spleen contains a large population of platelets, a rich source of "high uptake" phosphoglycoproteins that are pinocytosed by the phosphomannosyl recognition system present on fibroblasts (2) .
We found that leupeptin or EP475, two thiol-protease inhibitors, were able to partially correct the 8-galactosidase deficiency in fl-gal-/neur fibroblasts but had no effect on neuraminidase levels. These results agree with those of Suzuki et al. ( 15) , but differ from those of Galjaard et al. ( 5 ) who reported leupeptin to be effective in correcting both P-galactosidase and neuraminidase. Our results suggest that P-galactosidase is rapidly degraded by proteases in the lysosomes of P-gal-lneur cells but that the addition of protease inhibitor leupeptin inhibits the process and allows P-galactosidase levels to increase. The absence of an effect of leupeptin on neuraminidase levels could have at least two explanations: 1 ) the accelerated neuraminidase turnover may be mediated by a protease which is not sensitive to leupeptin or 2) the missing "corrective factor" may be necessary not only to stabilize neuraminidase but also required for "activation" of its catalytic activity. In this case, leupeptin would not be expected to replace the "corrective factor." Overall our results are consistent with those recently published by d'Azzo et al. (3) and provide further evidence that combined P-galactosidase neuraminidase deficiency is not the result of a defect in the structural gene for either P-galactosidase or neuraminidase but is due to a defect in a glycoprotein factor that is required to protect these enzyrnes from degradation and allow their expression in lysosomes. The phenotypic correction of P-galactosidase by leupeptin and "corrective factor" suggests two approaches to therapy, at least for the /I-galactosidase component of this disorder.
